Bringing Cardiology to the Forefront

Each year, MedPSU Conference invites distinguished clinician-scientists whose work is reshaping their respective fields. This year's cardiology keynote session drew considerable attention, with a packed auditorium of cardiologists, internists, residents, and medical students eager to hear about innovations in heart failure management — a condition that affects tens of millions of people worldwide and remains one of the leading causes of hospitalization in most countries.

Key Themes from the Keynote

The session covered several interconnected themes that reflect the current state of cardiology research and practice:

1. The Four-Pillar Approach to HFrEF Management

The speaker outlined how heart failure with reduced ejection fraction (HFrEF) management has been transformed by four evidence-based drug classes — ACE inhibitors/ARBs/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. The emphasis was on implementation: despite robust trial evidence, many eligible patients worldwide are not receiving all four pillars at guideline-recommended doses. Closing this treatment gap, the speaker argued, could prevent a significant number of preventable hospitalizations and deaths.

2. SGLT2 Inhibitors Beyond Diabetes

A substantial portion of the talk focused on the landmark trials that established SGLT2 inhibitors (originally developed for type 2 diabetes) as first-line heart failure therapy regardless of diabetes status. The speaker highlighted the importance of understanding the cardiorenal mechanisms behind these drugs — effects that go well beyond glucose control — and called on internists and primary care physicians to become familiar with their use.

3. Remote Monitoring and Digital Cardiac Care

Implantable hemodynamic sensors, wearable ECG devices, and AI-driven remote monitoring platforms are enabling earlier detection of decompensation. The speaker reviewed evidence for pulmonary artery pressure monitoring in ambulatory heart failure management and discussed how telemedicine is reshaping post-discharge care protocols.

4. Equity in Heart Failure Care

Acknowledging that advances in guideline-directed therapy have not reached all populations equally, the speaker urged conference attendees to consider structural and systemic factors — including medication cost, geographic access, and health literacy — that determine whether patients actually benefit from therapeutic advances.

Key Takeaways for Attendees

  • Optimize all four pillars of HFrEF therapy in eligible patients before exploring advanced options.
  • SGLT2 inhibitors are now standard of care in heart failure, not just a diabetes drug.
  • Digital tools are practical, evidence-supported, and increasingly accessible.
  • Addressing health equity is a clinical responsibility, not just a policy concern.

Why This Matters Beyond Cardiology

Heart failure is a condition that intersects with nephrology, endocrinology, geriatrics, and primary care. The session served as a reminder that advances in any specialty can — and should — inform practice across the broader medical community. The recording of this keynote session will be available to registered conference participants through the MedPSU online portal.